By Lisa Beilfuss
Gilead Sciences Inc. said Chief Executive John Martin's total
compensation package rose 23% to about $19 million in 2014, a year
in which the company's revenue more than doubled because of its
blockbuster hepatitis-C drug Sovaldi.
Mr. Martin's total stock and option award was $13.6 million, up
from $10.3 million in 2013. The board raised his salary 2.4% to
$1.6 million and awarded a bonus of $3.7 million, up 5% from a
2013.
"We are pleased to report that Gilead had strong financial
performance across all of our therapeutic areas," the company said
in a filing with Securities and Exchange Commission.
In 2014, Gilead's sales rose to $7.31 billion from $3.12
billion, and its earnings increased to $3.46 billion from $787
million. The improvement was due largely to Sovaldi, a hepatitis C
drug that was approved by the Federal Drug Administration at the
end of 2013 and has a cure rate exceeding 90%.
Write to Lisa Beilfuss at lisa.beilfuss@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires